ARCH Venture Partners rises to the top of STAT’s 2023 biotech VC rankings
Long-running firm ARCH Venture Partners has topped STAT's annual ranking of biotech venture capital performance.
This article is adapted from the 2023 edition of STAT’s annual report, “Ranking biotech’s top venture capital firms.”
ARCH Venture Partners, the long-running investment firm that in recent years has dedicated itself to backing biotechs with grandiose plans, also delivered some of the best returns on outside investors’ money, according to the 2023 edition of STAT’s annual ranking of biotech venture capital performance.
What's Your Reaction?
